DOCSLIB.ORG

(Medically) Complicated Thursday, June 9, 2016 9:30 Am-12:30 Pm

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Medically) Complicated Thursday, June 9, 2016 9:30 Am-12:30 Pm CE Course Handout It's (Medically) Complicated Thursday, June 9, 2016 9:30 a.m.-12:30 p.m. Welcome! It’s (Medically) Complicated! Thursday, June 9, 2016 It's (Medically) Complicated ADHA CLL Annual Session, Pittsburgh, PA Thomas A. Viola, R.Ph, C.C.P. [email protected] Lillian J. Caperila, RDH, BSDH, M.Ed. [email protected] 1 Program Objectives Program Objectives Pharmacology Hygiene Plan • Review the prominent disease states found in the • Discuss the changing paradigm in caries prevention medically-complex patient utilizing risk assessments and consideration with • Distinguish between the states of xerostomia and complex polypharmacy patients hyposalivation • Select effective fluoride therapy using calcium & • Recognize the protective functions of saliva and its phosphate in professional and take-home care. role in prevention • Integrate critical thinking skills and implement • Explain and compare disease-induced and medication-induced xerostomia effective patient care strategies considering the most common chronic diseases. © 2014 Viola & Caperila - All Rights Reserved 3 © 2014 Viola & Caperila - All Rights Reserved 4 Case Study Case Study • 57 year-old male • Patient is diabetic and was a • Last recare visit May 2012 former smoker • Generalized advanced • Statins to control cholesterol chronic periodontal • LDL (148); HDL (56) disease • Rx dietary changes • Significant medical history: • Reduced high fructose and • BP is 140/88 carbohydrates • Monitors glucose level • Began walking 3-4 times week for 1-2 miles each day © 2014 Viola & Caperila - All Rights Reserved 5 © 2014 Viola & Caperila - All Rights Reserved 6 Dental History Dental – Periodontal Exam Radiographic survey • Present and missing teeth • Pathology: caries, lesions, restored teeth, tori, root exposure etc… • Periodontal exam: • Probing 6 sites, mobility, recession, furcation involvement, occlusal assessment… • Gingival description • Active bleeding, exudate • Sensitivity, pain • Salivary flow 8 © 2014 Viola & Caperila - All Rights Reserved © 2014 Viola & Caperila - All Rights Reserved Patient Education Plan Clinical Phenotype: Discuss and document… 1. Medical & dental information 2. Oral examination & radiographs • Nutrition assessment • Lifestyle patterns What is missing here in your • Patient’s at-home oral care diagnosis and treatment plan? © 2014 Viola & Caperila - All Rights Reserved 9 © 2012 Thomas A. Viola, R.Ph., C.C.P. All Rights Reserved 10 Pathogenic burden? Salivary Diagnostic Tests: • PerioPath® test • MyPerioProgress ® report © 2014 Viola & Caperila - All Rights Reserved 11 12 CAMBRA: Diagnostics drives treatment Contributory Risk Factors • Scaling & root planing therapy • Antimicrobial mouthrinses • Host modifying medicaments: – Low dose doxycycline hyclate (Periostat™) – Site specific antibiotic (Arestin™, Atridox™) Salivary Diagnostics: How it is changing our approach to diagnosis, risk assessment, and treatment of periodontal disease. Bader H & Arndt H. Ineedceonline: PennWell® publication Feb 2013-Jan 2016. 13 CAMBRA: Caries Management By Risk Assessment CAMBRA: CAMBRA: General Health Factors Clinical Risk Factors: Dental Hygiene Treatment Plan: CAMBRA: updated risks . Recent hospitalization and reason? . General observation of patient’s appearance, gait • Removable partial dentures and cognitive capabilities • History of extensive prosthodontic or restorative therapy . Take vital signs and record/w date • Over 60 years of age . List names of drugs/herbal supplements • Smoking . Record the daily dosage and frequency (compliance?) • Infectious contact . Research the drug list: . side effects . interactions that may alter treatment outcomes Roberts, D. Maragliano, R. Chapman R. Put the Plan into Action, Dimensions of Dental Hygiene, June 2011 © 2014 Viola & Caperila - All Rights Reserved 18 Dental-Specific Pharmacology, Interactions, Drug interaction & oral conditions and Clinical References Apps available for mobile devices Dental-Specific Pharmacology, Interactions, www.AADMD.org/resources/additionalresources and Clinical References Today’s Review of Disease States Economic Burden • Cardiovascular disease • Diabetes • The mean annual spending on adult dental care peaks • Respiratory (COPD) between the ages of 55 to 64 del Aguila et al, 2002 • GERD dental caries account for about half of this spending • Alzheimer's • Parkinson’s • Americans spent an estimated $108 billion on dental • Chemotherapy & Head and services in 2010 Neck Radiation Patients • Projected increase to $180 billion by 2020. Truffer et al 2010 © 2012 Thomas A. Viola, R.Ph., C.C.P. All Rights Reserved 23 Cardiovascular Disease . The function of the cardiovascular system is to supply oxygen via the blood to all areas of the body. This is accomplished through the contraction of CARDIOVASCULAR DISEASE the heart and actions of the blood vessels. © 2014 Viola & Caperila - All Rights Reserved 25 © 2014 Viola & Caperila - All Rights Reserved 26 Cardiovascular Disease Hypertension Goal of Treatment Drugs Employed . Cardiovascular disease refers to disease of the Reduce plasma volume Diuretics heart and blood vessels that result in this failure. Dilate blood vessels ACEI’s, ARB’s, CCB’s, • Hypertension Alpha-1 Blockers • Coronary Artery Disease Reduce cardiac output • Cardiac Arrhythmia (via SANS) Beta-1 Blockers, • Congestive Heart Failure clonidine © 2014 Viola & Caperila - All Rights Reserved 27 © 2014 Viola & Caperila - All Rights Reserved 28 Coronary Artery Disease Congestive Heart Failure Goal of Treatment Drugs Employed Goal of Treatment Drugs Employed Reduce plasma volume Diuretics Increase coronary artery flow Nitrates, CCB’s Dilate blood vessels ACEI’s, ARB’s, CCB’s Reduce oxygen demand Beta-1 Blockers Reduce contraction rate Beta-1 Blockers Inhibit progression of disease Antihyperlipidemic Agents Increase cardiac contractility Digoxin Prevent thromboembolism Antithromboembolic Agents Prevent thromboembolism Antithromboembolic Agents © 2014 Viola & Caperila - All Rights Reserved 29 30 © 2014 Viola & Caperila - All Rights Reserved The Epinephrine Question Classification of Cholesterol levels Total Cholesterol • The benefit of using epinephrine to achieve profound anesthesia may outweigh the risk in patients with – Under 200 Desirable controlled cardiovascular disease. – 200-239 Borderline high – 240 and above High • Pain-induced stress leads to the release of endogenous epinephrine. • This may exacerbate cardiovascular disease. 31 32 © 2014 Viola & Caperila - All Rights Reserved © 2014 Viola & Caperila - All Rights Reserved Classification of Cholesterol levels Classification of Cholesterol levels LDL Cholesterol HDL Cholesterol • Less than 100 Optimal! • Under 40 Low • 100-129 Near-optimal • Over 60 High • 130-159 Borderline high *Optimal HDL should be >50 for women • 160-189 High Triglycerides • 190 and above Very high • Under 150 Optimal • 150-199 Borderline high • 200 and above High © 2014 Viola & Caperila - All Rights Reserved 33 © 2014 Viola & Caperila - All Rights Reserved 34 Dental Hygiene: Cardiovascular Dental Hygiene: Cardiovascular Observation during examination: • Face, arms or legs: numbness or weakness mainly on one When is best time to schedule this patient? side of body • Brain: confusion, trouble speaking, dizziness, loss of balance, What should be in your office emergency kit? bad headaches At visit – Ask if experienced an MI in past 30 days? • Eyes: trouble seeing from one or both • Stomach: throwing up or urge to • Legs/Body: feeling tired and trouble walking http://www.dentistryiq.com/articles/2013/06/heart-disease-and-stroke-update.html http://www.dentistryiq.com/articles/2013/06/heart-disease-and-stroke-update.html 35 36 Emergency Protocol* Patients with risk factors for coronary heart disease and experience “chest pain” Dental Hygiene: Cardiovascular 1. Take & record vital signs (BP over 180/110 Therapeutic Treatment: contraindicated for treatment that day) • Pain management pre-treatment 2. Administer 0.4mg tab of nitroglycerin sublingually or • 1-2 metered dose of spray (0.3 - 0.6mg) Mechanical removal of biofilm, pathogens 3. Provide Oxygen – flow rate 4 liters/min. to 6 • Altering immune response with selective antibiotics liters/min. via nasal cannula • Treating hypersensitivity – topical fluoride varnish 4. If pain doesn’t subside in 3 minutes, repeat dose of nitroglycerin 5-15 minutes 5. Chest pain that persists after 3 doses is most likely an Take-home agents: MI • Antimicrobial dentifrice/rinses 6. Pain persists – administer a 325 mg uncoated aspirin • Supplemental fluoride & calcium/phosphate products and CALL 911 7. Record all events in patient’s record • Power toothbrush, dental floss, proximal brushes *Tolle & Walters. Strategies for the Safe Treatment of Cardiovascular Patients. Dimensions in Dent Hyg. March 2015 38 37 © 2014 Viola & Caperila. All Rights Reserved Dental Hygiene: Cardiovascular Dental Hygiene: Cardiovascular Treating hypersensitivity: root exposure “dry mouth symptoms” Avoid use of petroleum jelly on lips = causes dehydration Rx: cocoa butter Avoid lemon glycerin swabs or crushing pills in fruit jam to assist in swallowing = dental caries risk If hydrogen peroxide mouthrinse used - must be diluted to neutralize acidity © 2014 Viola & Caperila - All Rights Reserved 39 Morris, D, & Sadowsky, J. Heart-Friendly Oral Health Care. Dimensions in Dent Hygiene. March 2011: Vol. 9, No 3. pp74-79. Dental Hygiene: Cardiovascular Take-home products DIABETES © 2014 Viola & Caperila - All Rights Reserved 41 © 2014
Load more

Recommended publications
  • Hypersalivation in Children and Adults
    Pharmacological Management of Hypersalivation in Children and Adults Scope: Adult patients with Parkinson’s disease, children with neurodisability, cerebral palsy, long-term ventilation with drooling, and drug-induced hypersalivation. ASSESSMENT OF SEVERITY/RESPONSE TO TREATMENT: Severity of drooling can be assessed subjectively via discussion with patients and their carers/parents and by observation. Amount of drooling can be quantified by measuring the number of bibs required per day and this can also be graded using the Thomas-Stonell and Greenberg scale: • 1 = Dry (no drooling) • 2 = Mild (moist lips) • 3 = Moderate (wet lips and chin) • 4 = Severe (damp clothing) CONSIDERATIONS FOR PRESCRIBING/TITRATION No evidence to support the use of one particular treatment over another. Drug choice is to be determined by individual patient factors. When prescribing/titrating antimuscarinic drugs to treat hypersalivation always take account of: • Coexisting conditions (for example, history of urinary retention, constipation, glaucoma, dental issues, reflux etc.) • Use of other existing medication affecting the total antimuscarinic burden • Risk of adverse effects Titrate dose upward until the desired level of dryness, side effects or maximum dose reached. Take into account the preferences of the patients and their carers/ parents, and the age range and indication covered by the marketing authorisations (see individual summaries of product characteristics, BNF or BNFc for full prescribing information). FIRST LINE DRUG TREATMENT OPTIONS FOR ADULTS
    [Show full text]
  • Laryngopharyngeal Reflux; PPI = Proton Pump Inhibitors; RSS-12 = Reflux Symptom Score-12
    Journal of Clinical Medicine Review Laryngopharyngeal Reflux: A State-of-the-Art Algorithm Management for Primary Care Physicians 1,2,3,4,5, , 1,4,5, 6 7 Jerome R. Lechien * y , Sven Saussez y, Vinciane Muls , Maria R. Barillari , 8 2,3,5, 9, Carlos M. Chiesa-Estomba , Stéphane Hans z and Petros D. Karkos z 1 Department of Human Anatomy and Experimental Oncology, Mons School of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), B7000 Mons, Belgium; [email protected] 2 Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), 92150 Paris, France; [email protected] 3 Department of Otolaryngology-Head & Neck Surgery, Ambroise Paré Hospital, APHP, Paris Saclay University, 92150 Paris, France 4 Department of Otolaryngology-Head & Neck Surgery, CHU Saint-Pierre, Faculty of Medicine, University Libre de Bruxelles, 1000 Brussels, Belgium 5 Department of Otolaryngology-Head & Neck Surgery, CHU Ambroise Paré, 92150 Paris, France 6 Division of Gastroenterology and Endoscopy, CHU Saint-Pierre, Faculty of Medicine, University Libre de Bruxelles, 1000 Brussels, Belgium; [email protected] 7 Division of Phoniatrics and Audiology, Department of Mental and Physical Health and Preventive Medicine, University of Naples SUN, 34103 Naples, Italy; [email protected] 8 Department of Otorhinolaryngology-Head & Neck Surgery, Hospital Universitario Donostia, 00685 San Sebastian, Spain; [email protected] 9 Department of Otorhinolaryngology and Head and Neck Surgery, AHEPA University Hospital, Thessaloniki Medical School, 54621 Thessaloniki, Greece; [email protected] * Correspondence: [email protected]; Tel.: +32-65-373-584 Authors have equally contributed to the paper’s supervision and should be considered as co-first authors.
    [Show full text]
  • Etiologic Factors of Hyposalivation and Consequences for Oral Health
    QUINTESSENCE INTERNATIONAL Etiologic factors of hyposalivation and consequences for oral health Peter Tschoppe, Dr Med Dent1/Michael Wolgin, Dr Med Dent2/ Nicole Pischon, Dr Med Dent Habil2/ Andrej M. Kielbassa, Dr Med Dent Habil3 Hyposalivation is represented by a reduced salivary flow rate and can be caused by etiolog- ic factors such as systemic diseases and intake of various medications or by radiotherapy following head and neck cancer. The aim of this review was to compile data about the qualitative and quantitative changes of salivary components during hyposalivation, and to summarize their consequences for oral health. A Medline/PubMed/Scopus search was con- ducted to identify and summarize articles published in English and German that reported on etiology of hyposalivation and changes in the salivary composition due to hyposalivation of different origins. The search revealed 94 articles, 71 of which were original articles. Apart from the reduction of the salivary flow rate, the quality of saliva is strongly altered because of systemic diseases, medications, and radiotherapy, including increased viscosity and pH shift to more acidic values and changes in salivary protein compositions. Furthermore, hypo - salivation may be accompanied by pronounced shifts in specific microbial components, in particular toward a highly acidogenic microflora. Moreover, therapy of hyposalivation is often restricted to palliative treatment (ie, saliva substitutes or gels). To prevent tooth tissue de - mineralization, clinicians should consider saliva
    [Show full text]
  • Clozapine-Induced Hypersalivation
    Medicines Information Bulletin Vol. 15 No. 1 February 2017 Clozapine-induced hypersalivation This bulletin is an update to a previously issued bulletin about clozapine-induced hypersalivation (vol 11 no 3, Oct 2013). There is a current UK shortage of hyoscine hydrobromide (Kwells) tablets – this is due to a lack of raw ingredient and it is not clear when this shortage may be resolved. CPSU has exhausted its stocks. In the meantime we have procured a supply of hyoscine from Australia however, as it is being imported, we don’t have a firm date of delivery – it is expected to arrive within a matter of days and prescribers will be notified when we have stock available. Please do not start any new patients on hyoscine until the imported version is available. Prescribers will be notified by our dispensary staff if we are unable to fulfil a repeat prescription for hyoscine for any patients already prescribed it and they will be asked to make a decision about which alternative is most suitable. We hope the information in this bulletin will help inform the choice of alternative. The information contained in this document includes the use of hyoscine tablets, as these are usually our first line treatment option for hypersalivation, however it is intended that the following information will allow prescribers to select alternative options that are suitable for their patients until hyoscine becomes available again. Suggested doses and methods of administration for the Trust’s preferred options: Priority of Drug Method of Dose Administration Secondary care use administration cost for max dose/28 days FIRST LINE Hyoscine Sublingual tablet * 300mcg daily.
    [Show full text]
  • Management of Oral Secretions in Neurological Disease
    This is a repository copy of Management of oral secretions in neurological disease.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/117160/ Version: Accepted Version Article: McGeachan, A.J. and Mcdermott, C.J. orcid.org/0000-0002-1269-9053 (2017) Management of oral secretions in neurological disease. Practical Neurology, 17 (2). pp. 96-103. ISSN 1474-7758 https://doi.org/10.1136/practneurol-2016-001515 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ The Management of Oral Secretions in Neurological Disease: A Review Word Count: 2566 Dr ALEXANDER J MCGEACHAN MBChB 1 & Dr CHRISTOPHER J. MCDERMOTT PhD 2 Corresponding author: Dr Christopher McDermott PhD FRCP, Reader in Neurology Sheffield
    [Show full text]
  • Journal of Gastroenterology & Digestive Systems
    ISSN: 2640-7477 Mini Review Article Journal of Gastroenterology & Digestive Systems Side Effect of Antipsychotic Drugs on the Gastrointestinal Tract: A Review of the Literature Volkov VP Tver center of judicial examinations, Russia *Corresponding author Volkov VP, Tver center of judicial examinations, Russia Submitted: 11 Mar 2020; Accepted: 15 May 2020; Published: 01 Jun 2020 Summary The antipsychotic preparations which are widely used in medical practice possess an extensive range of the negative side effects including operating on organs of system of digestion. In the offered review influence of antipsychotics on a digestive tract is considered. Keywords: Antipsychotic Preparations, Side Effect, Digestive Tract believed that hypersalivation may be associated with an increase in the secretory function of the salivary glands, as well as with a Introduction violation of swallowing due to dysfunction of the upper digestive Currently, psychotropic drugs are among the most popular tract. pharmacological agents [1-3]. However, these medications have a wide range of side effects that have an undesirable negative impact The severity of hypersalivation is dose-dependent, and tolerance on many tissues, organs and systems of the patient’s body [4, 5]. to this effect develops over time [13]. Hypersalivation increases One of the targets of this negative effect of AP is the digestive during sleep, which is fraught with the danger of saliva aspiration system [6-8]. This review of the literature is devoted to the effect and the development of aspiration pneumonia. This complication of AP on the gastrointestinal tract [9, 10]. is especially common in patients with excessive sedation and prolonged physical fixation [1].
    [Show full text]
  • Aspiration and Swallowing in Parkinson's Disease:Two Hundred
    Global Journal of Otolaryngology ISSN 2474-7556 Mini Review Glob J Otolaryngol - Volume 10 Issue 3 September 2017 Copyright © All rights are reserved by Michael AB Naafs DOI: 10.19080/GJO.2017.10.555789 Aspiration and Swallowing in Parkinson’s Disease :Two Hundred Years Later Michael AB Naafs* Naafs International Health Consultancy, Europe Submission: September 06, 2017; Published: September 18, 2017 *Corresponding author: Michael AB Naafs, Internist-endocrinologist with a long clinical career in internal medicine and endocrinology, Naafs International Health Consultancy, Dutch, Europe, Email: Abstract In this mini-review the developments in the reesarch and treatment of swallowig disorders and the subsequent impairments in cough function in Parkinson’s disease patients are discussed. Therapies for drooling and dysphagia are discussed in a disease existing this year for exactly two hundred years. Future directions to a more functional than pathogen directed approach to aspiration pneumonia, still the main pneumonia by intensifying research will be essential. cause of death in Parkinson’s patients are discussed. Breaking or reversal of the cycle swallowing disorder, impaired cough reflex, aspiration Introduction Parkinson’s Disease(PD) can lead to problems with swallowing bolus,prolonged swallowing time,limited tongue and mandibular in between 30-100% of patients at anytime during the disease [1,2] include orofacial tremor,difficulty in forming a cohesive food extension during mastication and the presence of repititive anteroposterior movements of the tongue during bolus propulsion Although James Parkinson described swallowing difficulties in one (lingual festination). Pharyngeal impairments include delayed publications on this subject appeared in the 80’s and 90’s of the of his patients in “An Essay on the Shaking Palsy” in 1817 the first pharyngeal response with consequent stasis in the vallecululae last century [3-5].
    [Show full text]
  • Diagnosis and Treatment of Neurogenic Dysphagia – S1
    Dziewas et al. Neurological Research and Practice (2021) 3:23 Neurological Research https://doi.org/10.1186/s42466-021-00122-3 and Practice GUIDELINES Open Access Diagnosis and treatment of neurogenic dysphagia – S1 guideline of the German Society of Neurology Rainer Dziewas1,2* , Hans-Dieter Allescher3, Ilia Aroyo4, Gudrun Bartolome5, Ulrike Beilenhoff6, Jörg Bohlender7, Helga Breitbach-Snowdon8, Klemens Fheodoroff9, Jörg Glahn10, Hans-Jürgen Heppner11, Karl Hörmann12, Christian Ledl13, Christoph Lücking14, Peter Pokieser15, Joerg C. Schefold16, Heidrun Schröter-Morasch17, Kathi Schweikert18, Roland Sparing19, Michaela Trapl-Grundschober20, Claus Wallesch21, Tobias Warnecke1, Cornelius J. Werner22, Johannes Weßling23, Rainer Wirth24 and Christina Pflug25 Abstract Introduction: Neurogenic dysphagia defines swallowing disorders caused by diseases of the central and peripheral nervous system, neuromuscular transmission, or muscles. Neurogenic dysphagia is one of the most common and at the same time most dangerous symptoms of many neurological diseases. Its most important sequelae include aspiration pneumonia, malnutrition and dehydration, and affected patients more often require long-term care and are exposed to an increased mortality. Based on a systematic pubmed research of related original papers, review articles, international guidelines and surveys about the diagnostics and treatment of neurogenic dysphagia, a consensus process was initiated, which included dysphagia experts from 27 medical societies. Recommendations: This guideline consists of 53 recommendations covering in its first part the whole diagnostic spectrum from the dysphagia specific medical history, initial dysphagia screening and clinical assessment, to more refined instrumental procedures, such as flexible endoscopic evaluation of swallowing, the videofluoroscopic swallowing study and high-resolution manometry. In addition, specific clinical scenarios are captured, among others the management of patients with nasogastric and tracheotomy tubes.
    [Show full text]
  • Oral Medicine: 4. Dry Mouth and Disorders of Salivation
    OralMedicine-UpdatefortheDentalTeam This series provides an overview of current thinking in the more relevant areas of Oral Medicine, for primary care practitioners. The series gives the detail necessary to assist the primary dental clinical team caring for patients with oral complaints that may be seen in general dental practice. Space precludes inclusion of illustrations of uncommon or rare disorders. Approaching the subject mainly by the symptomatic approach, as it largely relates to the presenting complaint, was considered to be a more helpful approach for GDPs rather than taking a diagnostic category approach. The clinical aspects of the relevant disorders are discussed, including a brief overview of the aetiology, detail on the clinical features and how the diagnosis is made, along with guidance on management David H Felix Jane Luker Crispian Scully and when to refer, in addition to relevant websites which offer further detail. Oral Medicine: 4. Dry Mouth and Disorders of Salivation Specialist referral may be indicated if the via various antimicrobial components Digestion Practitioner feels: such as mucin, histatins, lysozyme and Lubrication The diagnosis is unclear; lactoferrin, and via specific antibodies to a Buffering A serious diagnosis is possible; range of micro-organisms that the host has Mineralization Systemic disease may be present; encountered. Tissue coating Unclear as to investigations indicated; Salivary gland secretion from Anti-microbial Complex investigations unavailable in the major (parotid, submandibular and Table 1. Functions of saliva. primary care are indicated; sublingual) and minor glands (multiple Unclear as to treatment indicated; mucous glands scattered throughout Treatment is complex; the mouth – especially the lips and Iatrogenic Treatment requires agents not readily soft palate), is mainly under neural – Drugs available; control, under the influence of the – Irradiation autonomic nervous system, although Unclear as to the prognosis; – Graft versus host disease The patient wishes this.
    [Show full text]
  • Sialorrhea-A Management Challenge in Dental Practice
    Review articles Annals and Essences of Dentistry doi:10.5368/aedj.2013.5.2.4.4 SIALORRHEA-A MANAGEMENT CHALLENGE IN DENTAL PRACTICE. 1 1 Ravishankar P L Professor and Head 2Leela Krishna Prasad Ch 2Professor 3Siva Nagaendra Reddy 3 Professor and Head 1 Department of Periodontics, Sri Sai Dental College Srikakulam, Andhra pradesh 2 Department of Oral Medicine and radiology, Maharana pratap Dental college and Hospital, Kanpur, Uttar pradesh 3 Department of Oral and Maxillofacial Surgery, Sri Sai Dental College Srikakulam, Andhra pradesh ABSTRACT: Sialorrhea also known as ptyalism or drooling, can be defined as salivary incontinence or the involuntary spillage of saliva over the lower lip. Drooling could be caused by excessive production of saliva, inability to retain saliva within the mouth, or problems with swallowing. Drooling can lead to functional and clinical consequences for patients, families, and caregivers. Physical and psychosocial complication includes maceration of skin around the mouth, secondary bacterial infection, bad odour, dehydration and social stigmatisation. This article provides a review of the physiology, pathogenesis, clinical oral manifestations, and therapeutic options for sialorrhea. Oral health care professionals should recognize the importance of sialorrhea as a possible indicator or complication of a variety of disease states of the oropharynx and esophagus as well as its impact on the patient's physical and social quality of life. KEYWORDS: Sialorrhea, Drooling,Ptyalism, Ptyalorrhoea, Hyper salivation INTRODUCTION Saliva is produces by major salivary glands (parotid, should be used to achieve the best diagnostic and Submandibular and sublingual) and many minor salivary therapeutic approaches.2 glands situated in the oral cavity.
    [Show full text]
  • WAPDC Alert: Atropine Eye Drops for Hypersalivation
    WA.PDC PSYCHOTROPIC DRUG COMMITTEE WA PSYCHOTROPIC DRUG COMMITTEE (WAPDC) ALERT Atropine Eye Drops for Hypersalivation Position statement Use of sublingual atropine eye drops for the treatment of antipsychotic-induced hypersalivation may be an option1 for patients in whom the anticholinergic load is considered acceptable and where the patient is able to manipulate the bottle to extract the dose safely. Consensus agreement Sublingual atropine drops are commonly used ‘off label’2 as a treatment option for management of clozapine-induced hypersalivation. The pharmacokinetics of atropine and susceptibility to its effects varies considerably between patients. Atropine is toxic in overdose and deaths have occurred after administration of just 15mg oral atropine. When prescribing atropine drops for this indication, the ability of the patient to manipulate the bottle to reliably extract the correct dose and the risk of systemic anticholinergic load should be considered. Atropine eye drops 1% can be used sublingually, one or two drops two or three times a day. Alternative anticholinergic medications to atropine drops for hypersalivation (also ‘off label’) include: Amitriptyline - also toxic in overdose and will cause systemic effects like constipation Hyoscine - sublingual or oral but this has the same systemic effects as atropine drops. Benztropine - also toxic in overdose and will cause systemic effects like constipation Ipratropium spray sublingually – generally regarded as far less effective than atropine drops or systemic anticholinergics Glycopyrrolate – no convenient formulations are available here and the toxic effects are similar to atropine If anticholinergic medications are not effective in the treatment of hypersalivation α- adrenergic medications can be considered. There is only weak evidence available demonstrating efficacy for this group of medications which include: Clonidine Amisulpride# Terazosin# Moclobemide # The Statewide Medicines Formulary does not permit use of this medication for hypersalivation.
    [Show full text]
  • Gastroesophageal Reflux Disease (GERD)
    World Gastroenterology Organisation Global Guidelines GERD Global Perspective on Gastroesophageal Reflux Disease Update October 2015 Review team Richard Hunt UK/Canada David Armstrong Canada Peter Katelaris Australia Mary Afihene Ghana Abate Bane Ethiopia Shobna Bhatia India Min-Hu Chen China Myung Gyu Choi Korea Angelita Cristine Melo Brasil Kwong Ming Fock Singapore Alex Ford United Kingdom Michio Hongo Japan Aamir Khan Pakistan Leonid Lazebnik Russia Greger Lindberg Sweden Maribel Lizarzabal Venezuela Thein Myint Myanmar Joaquim Prado Moraes-Filho Brazil Graciela Salis Argentina Jaw Town Lin Taiwan Raj Vaidya India Abdelmounen Abdo Khartoum Anton LeMair Netherlands © World Gastroenterology Organisation 2015 WGO Global Guidelines GERD 2 Contents 1 Introduction 3 1.1 Cascades for GERD diagnosis and management 3 1.2 Definition and description of GERD 4 1.3 Epidemiology of GERD 5 2 Clinical features 6 2.1 Predisposing and risk factors 6 2.2 Symptomatology 7 2.3 Natural history 9 2.4 Alarm features 9 3 Diagnosis 10 3.1 Diagnostic considerations 10 3.2 Patient history and physical examination 13 3.3 Diagnostic tests for GERD 15 3.4 Differential diagnosis 17 3.5 Cascades for the diagnosis of GERD 18 4 Management 19 4.1 Management principles 19 4.2 Stepwise therapy 19 4.3 GERD treatment in pregnancy 23 4.4 Surgical interventions 24 4.5 Managing complications of GERD 24 4.6 Cascades for the management of GERD 25 5 Appendix 27 5.1 Abbreviations and definitions 27 5.2 Gold standard guidelines on GERD 28 5.3 Los Angeles classification of erosive
    [Show full text]